Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma
复制标题
醛酮还原酶家族 1 成员 B10 (AKR1B10) 在肿瘤中过度表达可预测肝细胞癌的总体生存率较差
DOI：
10.7150/jca.32768
复制
发表时间：
2019-01-01
影响因子：
3.9
通讯作者：
Yang, Zongguo
中科院分区：
文献类型：
--
作者：
Shi, Jia;Chen, Lixiang;Yang, Zongguo
AKR1B10过表达与多种人类恶性肿瘤发生相关然而，AKR1B10表达在肝细胞癌（HCC）患者中的预后价值仍存在争议。在本分析中，我们在GEO、TCGA和Oncomine数据库中评估了AKR1B10在HCC肿瘤中的表达，并基于TCGA谱进行了AKR1B10的生存分析。我们发现AKR1B10在7个GEO系列（GSE14520、GSE25097、GSE33006、GSE45436、GSE55092、GSE60502、GSE77314）和TCGA基因中在肿瘤中较非肿瘤显著过表达（均P < 0.05）。Oncomine数据库meta分析显示，与正常组织相比，AKR1B10在肝硬化、肝细胞发育不良和HCC中表达上调（均P < 0.05）。Kaplan-Meier分析显示，肿瘤中AKR1B10水平高与HCC患者总生存期（OS）降低显著相关（P < 0.05）。亚组分析显示，AKR1B10过表达与1年、3年、5年OS差相关（均P < 0.05）。此外，AKR1B10上调对OS的预后价值在无肝炎病毒（P = 0.00055）、白种（P = 0.0029）和无酒精（P = 0.013）的HCC中更为显著，在男性和女性（P = 0.014和P = 0.034）中都是如此。总之，在HCC患者中，AKR1B10在肿瘤中表达上调，并与较差的OS相关。
Overexpression of AKR1B10 correlated with tumorigenesis of many human malignancies; however, the prognostic value of AKR1B10 expression in patients with hepatocellular carcinoma (HCC) still remains controversial. In this analysis, AKR1B10 expression in HCC tumors were evaluated in GEO, TCGA and Oncomine databases, and a survival analysis of AKR1B10 based on TCGA profile was performed. We found that AKR1B10 was significantly overexpressed in tumors compared with nontumors in 7 GEO series (GSE14520, GSE25097, GSE33006, GSE45436, GSE55092, GSE60502, GSE77314) and TCGA profile (all P < 0.05). Meta-analysis in Oncomine database revealed that AKR1B10 was significantly upregulated in cirrhosis, liver cell dysplasia and HCC compared with normal tissues (all P < 0.05). Kaplan-Meier analysis demonstrated that high AKR1B10 in tumors were significantly associated with worse overall survival (OS) in HCC patients (P < 0.05). Subgroup analysis showed that AKR1B10 overexpression were associated with poor 1-year, 3-year and 5-year OS (all P < 0.05). In addition, prognostic values of AKR1B10 upregulation for OS were more significant in HCC with hepatitis-virus-free (P = 0.00055), White race (P = 0.0029) and alcohol-free (P = 0.013), and both in male and female (P = 0.014 and P = 0.034, respectively). In conclusion: AKR1B10 was upregulated in tumors and correlated with worse OS in HCC patients.